collection
MENU ▼
Read by QxMD icon Read
search

MMCBreast Collection

shared collection
251 papers 100 to 500 followers
https://www.readbyqxmd.com/read/28636861/timing-of-metastasis-in-breast-cancer
#1
Robert S Schwartz, John K Erban
New England Journal of Medicine, Volume 376, Issue 25, Page 2486-2488, June 2017.
June 22, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28632866/risks-of-breast-ovarian-and-contralateral-breast-cancer-for-brca1-and-brca2-mutation-carriers
#2
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu, David E Goldgar, Mary Beth Terry, Matti A Rookus, Douglas F Easton, Antonis C Antoniou, Lesley McGuffog, D Gareth Evans, Daniel Barrowdale, Debra Frost, Julian Adlard, Kai-Ren Ong, Louise Izatt, Marc Tischkowitz, Ros Eeles, Rosemarie Davidson, Shirley Hodgson, Steve Ellis, Catherine Nogues, Christine Lasset, Dominique Stoppa-Lyonnet, Jean-Pierre Fricker, Laurence Faivre, Pascaline Berthet, Maartje J Hooning, Lizet E van der Kolk, Carolien M Kets, Muriel A Adank, Esther M John, Wendy K Chung, Irene L Andrulis, Melissa Southey, Mary B Daly, Saundra S Buys, Ana Osorio, Christoph Engel, Karin Kast, Rita K Schmutzler, Trinidad Caldes, Anna Jakubowska, Jacques Simard, Michael L Friedlander, Sue-Anne McLachlan, Eva Machackova, Lenka Foretova, Yen Y Tan, Christian F Singer, Edith Olah, Anne-Marie Gerdes, Brita Arver, Håkan Olsson
Importance: The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospective cancer risk estimates. Objectives: To estimate age-specific risks of breast, ovarian, and contralateral breast cancer for mutation carriers and to evaluate risk modification by family cancer history and mutation location. Design, Setting, and Participants: Prospective cohort study of 6036 BRCA1 and 3820 BRCA2 female carriers (5046 unaffected and 4810 with breast or ovarian cancer or both at baseline) recruited in 1997-2011 through the International BRCA1/2 Carrier Cohort Study, the Breast Cancer Family Registry and the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, with ascertainment through family clinics (94%) and population-based studies (6%)...
June 20, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28622841/do-online-prognostication-tools-represent-a-valid-alternative-to-genomic-profiling-in-the-context-of-adjuvant-treatment-of-early-breast-cancer-a-systematic-review-of-the-literature
#3
REVIEW
Hiba El Hage Chehade, Umar Wazir, Kinan Mokbel, Abdul Kasem, Kefah Mokbel
INTRODUCTION: Decision-making regarding adjuvant chemotherapy has been based on clinical and pathological features. However, such decisions are seldom consistent. Web-based predictive models have been developed using data from cancer registries to help determine the need for adjuvant therapy. More recently, with the recognition of the heterogenous nature of breast cancer, genomic assays have been developed to aid in the therapeutic decision-making. METHODS: We have carried out a comprehensive literature review regarding online prognostication tools and genomic assays to assess whether online tools could be used as valid alternatives to genomic profiling in decision-making regarding adjuvant therapy in early breast cancer...
June 3, 2017: American Journal of Surgery
https://www.readbyqxmd.com/read/28615971/clinical-use-of-the-oncotype-dx-genomic-test-to-guide-treatment-decisions-for-patients-with-invasive-breast-cancer
#4
REVIEW
Terri P McVeigh, Michael J Kerin
Implementation of the Oncotype DX assay has led to a change in the manner in which chemotherapy is utilized in patients with early stage, estrogen receptor (ER)-positive, node-negative breast cancer; ensuring that patients at highest risk of recurrence are prescribed systemic treatment, while at the same time sparing low-risk patients potential adverse events from therapy unlikely to influence their survival. This test generates a recurrence score between 0 and 100, which correlates with probability of distant disease recurrence...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28606707/disparities-in-compliance-with-the-oncotype-dx-breast-cancer-test-in-the-united-states-a-national-cancer-data-base-assessment
#5
Zachary Kozick, Ammar Hashmi, James Dove, Marie Hunsinger, Tania Arora, Jeffrey Wild, Mohsen Shabahang, Joseph Blansfield
BACKGROUND: Oncotype DX (ODX) is a multi-gene tumor assay for breast cancer patients. Our objective is to assess whether eligible ODX patients received the test and whether recommendations were followed based on respective risk. METHODS: We retrospectively analyzed testing in patients deemed eligible for ODX using the National Cancer Data Base. RESULTS: A total of 158,235 patients met ODX eligibility criteria. Sixty-four percent of eligible patients did not receive the test...
June 9, 2017: American Journal of Surgery
https://www.readbyqxmd.com/read/28591529/are-small-breast-cancers-good-because-they-are-small-or-small-because-they-are-good
#6
Donald R Lannin, Shiyi Wang
The recent article by Welch et al. in the Journal showed clearly that since the adoption of widespread screening mammography, small breast cancers have increased in incidence over three times more than large cancers have decreased. This implies that many small cancers are not destined to progress..
June 8, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28589366/meta-analysis-of-pre-operative-magnetic-resonance-imaging-mri-and-surgical-treatment-for-breast-cancer
#7
REVIEW
Nehmat Houssami, Robin M Turner, Monica Morrow
BACKGROUND: Although there is no consensus on whether pre-operative MRI in women with breast cancer (BC) benefits surgical treatment, MRI continues to be used pre-operatively in practice. This meta-analysis examines the association between pre-operative MRI and surgical outcomes in BC. METHODS: A systematic review was performed to identify studies reporting quantitative data on pre-operative MRI and surgical outcomes (without restriction by type of surgery received or type of BC) and using a controlled design...
June 6, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28583398/the-emerging-world-of-breast-cancer-immunotherapy
#8
Mark R Nathan, Peter Schmid
Over the last few years, the developments around cancer immunotherapy (CIT) have led to a paradigm shift in the treatment of many different cancers, in particular melanoma, renal, bladder and lung cancers with a remarkable impact on response rate and, most importantly, overall survival. Breast cancer is most commonly considered to be a 'non-inflamed' cancer and so this shift has been less marked within its treatment. However, some subsets of breast cancer, most notably triple negative breast cancer, are deemed to be more 'inflamed' and therefore may prove to be an appropriate cohort for CIT...
June 2, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28558338/the-challenge-of-sustainability-in-healthcare-systems-frequency-and-cost-of-inappropriate-patterns-of-breast-cancer-care-the-e-pic-a-study
#9
Ilaria Massa, William Balzi, Costanza Burattini, Nicola Gentili, Lauro Bucchi, Oriana Nanni, Davide Gallegati, Andrea Pierini, Dino Amadori, Fabio Falcini, Mattia Altini
OBJECTIVES: In a context of decreasing economic health resources and a rise in health needs, it is urgent to face this sustainability crisis through the analysis of healthcare expenditures. Wastages, deriving from inappropriate interventions, erode resources which could be reallocated to high-value activities. To identify these areas of wastages, we developed a method for combining and analyzing data from multiple sources. Here we report the preliminary results of a retrospective cohort study evaluating the performance of breast cancer (BC) care at IRST, an Italian cancer institute...
May 27, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28560598/the-impact-of-residual-disease-after-preoperative-systemic-therapy-on-clinical-outcomes-in-patients-with-inflammatory-breast-cancer
#10
Faina Nakhlis, Meredith M Regan, Laura E Warren, Jennifer R Bellon, Judith Hirshfield-Bartek, Margaret M Duggan, Laura S Dominici, Mehra Golshan, Heather A Jacene, Eren D Yeh, Erin E Mullaney, Beth Overmoyer
BACKGROUND: Inflammatory breast cancer (IBC) is a rare and aggressive disease treated with multimodality therapy: preoperative systemic therapy (PST) followed by modified radical mastectomy (MRM), chest wall and regional nodal radiotherapy, and adjuvant biologic therapy and/or endocrine therapy when appropriate. In non-IBC, the degree of pathologic response to PST has been shown to correlate with time to recurrence (TTR) and overall survival (OS). We sought to determine if pathologic response correlates with oncologic outcomes of IBC patients...
May 30, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28529029/metaplastic-carcinoma-of-the-breast-is-more-aggressive-than-triple-negative-breast-cancer-a%C3%A2-study-from-a-single-institution-and-review-of%C3%A2-literature
#11
Dima El Zein, Melissa Hughes, Shicha Kumar, Xuan Peng, Tolutope Oyasiji, Hossam Jabbour, Thaer Khoury
BACKGROUND: We aimed to describe our experience with metaplastic breast carcinoma (MBC), evaluate its clinical outcome compared with triple-negative breast cancer (TNBC), and provide a through and comprehensive review of the literature to date. MATERIALS AND METHODS: We reviewed MBC cases (n = 46) from our institution. The following variables were recorded: tumor histologic subtype, Nottingham grade, tumor size, lymph node status, Tumor, Node, Metastases stage, biomarkers profile, patient's age and race, therapy modality (chemotherapy and radiation), and survival (disease-free survival [DFS] and overall survival [OS])...
April 26, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28528449/the-canadian-national-breast-screening-studies-are-compromised-and-their-results-are-unreliable-they-should-not-factor-into-decisions-about-breast-cancer-screening
#12
REVIEW
Daniel B Kopans
The Canadian National Breast Screening Studies were compromised by an unblinded allocation process and poor quality mammography. Contrary to the requirement that allocation in a randomized controlled trial (RCT) be blinded to avoid any possible intentional or unintentional subversion of a random allocation, all women in the CNBSS trials underwent a clinical breast examination prior to assignment to the study arm or the usual care arm. Women with abnormal clinical breast examinations were identified, and this information was available to the coordinators who then assigned the women on open lists...
May 20, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28532503/an-updated-predict-breast-cancer-prognostication-and-treatment-benefit-prediction-model-with-independent-validation
#13
Francisco J Candido Dos Reis, Gordon C Wishart, Ed M Dicks, David Greenberg, Jem Rashbass, Marjanka K Schmidt, Alexandra J van den Broek, Ian O Ellis, Andrew Green, Emad Rakha, Tom Maishman, Diana M Eccles, Paul D P Pharoah
BACKGROUND: PREDICT is a breast cancer prognostic and treatment benefit model implemented online. The overall fit of the model has been good in multiple independent case series, but PREDICT has been shown to underestimate breast cancer specific mortality in women diagnosed under the age of 40. Another limitation is the use of discrete categories for tumour size and node status resulting in 'step' changes in risk estimates on moving between categories. We have refitted the PREDICT prognostic model using the original cohort of cases from East Anglia with updated survival time in order to take into account age at diagnosis and to smooth out the survival function for tumour size and node status...
May 22, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28508184/nationwide-cross-sectional-adherence-to-mammography-screening-guidelines-national-behavioral-risk-factor-surveillance-system-survey-results
#14
Anand Narayan, Alexander Fischer, Zihe Zhang, Ryan Woods, Elizabeth Morris, Susan Harvey
PURPOSE: Varying recommendations about breast cancer screening have generated much confusion about when and how often to undergo mammography screening, yet there is limited population-based data about the extent to which patients adhere to various mammographic screening guidelines in practice. Our purpose was to evaluate population-based adherence to mammographic screening using criteria from major guideline-producing organizations. METHODS: Women aged 40-74 in the 2014 Behavioral Risk Factor Surveillance System survey were included...
May 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28521178/impact-of-2013-asco-cap-guidelines-on-her2-determination-of-invasive-breast-cancer-a-single-institution-experience-using-frontline-dual-color-fish
#15
M Ragazzi, A Bisagni, E Gasparini, E Kuhn, C Bassano, I Tamagnini, M Foroni, M Bortesi, G Falco, G Ferrari, L Braglia, L Savoldi, A Bologna, R Di Cicilia, G Bisagni, G Gardini
PURPOSE: The new ASCO/CAP guidelines published in 2013 (AC2013) significantly modified the scoring criteria for HER2-FISH, introducing the most controversial change to the HER2-equivocal category. We retrospectively evaluated the impact of AC2013 in a cohort of consecutive invasive breast cancers (IBCs) analyzed with frontline dual-color FISH. METHODS: 2788 consecutive IBCs were reclassified based on the AC2013 guidelines. Clinico-pathological features of equivocal IBCs were compared with HER2-negative and HER2-positive IBCs...
May 15, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28503075/imprint-cytology-versus-frozen-section-analysis-for-intraoperative-assessment-of-sentinel-lymph-node-in-breast-cancer
#16
Thalia Petropoulou, Antonia Kapoula, Aikaterini Mastoraki, Aikaterini Politi, Eleni Spanidou-Karvouni, Ioannis Psychogios, Ioannis Vassiliou, Nikolaos Arkadopoulos
INTRODUCTION: Sentinel lymph node (SLN) biopsy is the gold standard for surgical staging of the axilla in breast cancer (BC). Frozen section (FS) remains the most popular means of intraoperative SLN diagnosis. Imprint cytology (IC) has also been suggested as a less expensive and equally accurate alternative to FS. The aim of our study was to perform a direct comparison between IC and FS on the same SLNs of BC cases operated in a single center by the same surgical team. MATERIALS AND METHODS: Into this prospective study we enrolled 60 consecutive patients with histologically proven T1-T3 BC and clinically negative axilla...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28485826/triple-negative-breast-cancer-in-the-elderly-prognosis-and-treatment
#17
Henry G Kaplan, Judith A Malmgren, Mary K Atwood
Our objective is to characterize treatment of triple-negative breast cancer (TNBC) in older patients and measure mortality risk relative to younger women. We conducted a retrospective cohort study analysis of patients presenting with primary TNBC, age 25-93, stage I-III from 1990 to 2014, identified and tracked by our registry (n=771). Clinical characteristics were chart abstracted at diagnosis and follow-up. The Kaplan-Meier method was used to measure disease-specific survival (DSS) by age with Cox regression modeling for relative contribution of patient and clinical characteristics...
May 9, 2017: Breast Journal
https://www.readbyqxmd.com/read/28484921/preoperative-prediction-of-node-negative-disease-after-neoadjuvant-chemotherapy-in-patients-presenting-with-node-negative-or-node-positive-breast-cancer
#18
Brittany L Murphy, Tanya L Hoskin, Courtney Day N Heins, Elizabeth B Habermann, Judy C Boughey
BACKGROUND: Axillary node status after neoadjuvant chemotherapy (NAC) influences the axillary surgical staging procedure as well as recommendations regarding reconstruction and radiation. OBJECTIVE: Our aim was to construct a clinical preoperative prediction model to identify the likelihood of patients being node negative after NAC. METHODS: Using the National Cancer Database (NCDB) from January 2010 to December 2012, we identified cT1-T4c, N0-N3 breast cancer patients treated with NAC...
May 8, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28493552/multigene-assays-implications-for-breast-cancer-staging
#19
EDITORIAL
Frederick L Greene
No abstract text is available yet for this article.
May 11, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28433541/the-impact-of-2013-updated-asco-cap-her2-guidelines-on-the-diagnosis-and-management-of-invasive-breast-cancer-a-single-center-study-of-1739-cases
#20
Xiaofei Zhang, Ira Bleiweiss, Shabnam Jaffer, Anupma Nayak
BACKGROUND: The purpose of this study was to determine the impact of revised ASCO/CAP 2013 HER2 guidelines on the clinical practice of pathologists and oncologists. MATERIALS AND METHODS: Retrospective analysis of 1739 patients with invasive breast carcinoma who underwent reflex HER2 (fluorescence in situ hybridization [FISH]) testing, using both 2007 and 2013 guidelines (2007-2014). RESULTS: Using 2013 guidelines, 255 (15%; 95% confidence interval [CI], 13%-16%) cases were classified as HER2(+) as opposed to 186 (11%; 95% CI, 9%-12%) by 2007 guidelines (odds ratio [OR] 1...
March 29, 2017: Clinical Breast Cancer
label_collection
label_collection
6331
1
2
2017-05-05 19:11:10
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"